New Technology in Vaccine Engineering - RCPA
Transcript of New Technology in Vaccine Engineering - RCPA
![Page 1: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/1.jpg)
New Technology inVaccine Engineering
Anton MiddelbergAustralian Institute for Bioengineering and Nanotechnology
The University of Queensland, Australia
Viruses in MayKatoomba, August, 2012
![Page 2: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/2.jpg)
Introduction
Vaccination enormously successfulSmallpox eradicated, polio close
More to do15 M people still die annually, half children <5 yrsEmergent and re-emergent disease
Technological gap in approachesPasteur’s “Isolate-Inactivate-Inject” dominatesOpportunity to engineer better systems
![Page 3: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/3.jpg)
3
Modular Vaccine Design
with sites for insertion of optional modules
BASEhttp://www.indiamart.com/ajantaautoacc/front-guard.html#ajanta-grill-guard-for-tavera
MODULE MODULAR DESIGN+
http://www.ssa.ford.com/servlet/ContentServer?cid=1178863133817&pagename=FSSA%2FDFYPage%2FFord-Default&c=DFYPage&site=FSSA
Front guard
Viral antigen
![Page 4: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/4.jpg)
Murine Polyomavirus
X 72
CapsomereVirus-like Particle
(VLP or Capsid)VP1 Protein
![Page 5: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/5.jpg)
Antigen Insertion Sites on VLP Surface
![Page 6: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/6.jpg)
Bioprocess Engineering
Best available expressionin literature: 1 mg/L.OD
After factorial optimisation,Host selection and redesign:15-20 mg/L.OD
Confirmed 2-4 g/L in fed-batchE. coli fermentation.
J. Biotechnol. (2008), 134(1-2): 64-71
J. Biotechnol. (2010), 150(2): 224-231
![Page 7: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/7.jpg)
7
A practical model
Biotechnol. Bioeng. (2010), 107:550
![Page 8: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/8.jpg)
VP1 self-assembly in vitro
![Page 9: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/9.jpg)
9
Speedsame process for different virusestime from DNA to purified antigen < 1 weekprocessing can be automated
ScaleMakes protein using industrial biotechnology tools100M doses per kL of bacterial culture in 24 h
Safetywe make protein, not viruswe can sterile filter before virus assembly
The UQ Microbial Vaccine Platform (MVP)
![Page 10: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/10.jpg)
PurificationAnd Assembly
(48 h) >100,000 dosesper litre
1000L pilot= 100M doses
In 24 h
WaterGlucoseSaltsBacteria
Within 24 h2 g/l Soluble Antigen
Purification and Assembly
The UQ Microbial Vaccine Platform (MVP)
“Dose Excess” regime.Everyone can cultivate bacteria.
![Page 11: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/11.jpg)
11
Application of the Platform: Influenza
![Page 12: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/12.jpg)
12
Influenza
www.cdc.gov
http://microbiology2009.wikispaces.com/Influenza
Global ChallengeWhen the virus changes, existing vaccine does not work.
![Page 13: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/13.jpg)
13
H1N1 (2009): April 27th
![Page 14: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/14.jpg)
14
H1N1 (2009): May 27th
![Page 15: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/15.jpg)
15
H1N1 (2009): September 27th
![Page 16: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/16.jpg)
16
Influenza in a Connected World
Identify
ShareControl
People die while they wait for the new vaccine
![Page 17: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/17.jpg)
17
Vaccine available for in vivo testing
0 2 4 5 7
Laboratory Timeline (Days):
Rapid response for emergent virus
Microbial culture
Modular capsomere
Modular VLP
![Page 18: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/18.jpg)
18
Target Epitopes
Strain-specificHA1 – receptor binding regionsOther HA1 epitopes
Broadly cross-protectingM2e of matrix protein 2HA stalk regions
AssumeViruses
are Static
AssumeVirusesChange
![Page 19: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/19.jpg)
19
Target Epitopes
Strain-specificHA1 – receptor binding regionsOther HA1 epitopes
Broadly cross-protectingM2e of matrix protein 2HA stalk regions
AssumeVirusesChange
![Page 20: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/20.jpg)
20
Haemagglutinin Helix 190 Influenza A virus
http://viromag.files.wordpress.com/2009/02/influenza-virus-diagram.jpg
Receptor binding site.
Biology 101 – blocking the receptor binding site will block viral entry.
Glycosylation?Structure?
![Page 21: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/21.jpg)
21
Viralprotein
VP1
Target epitope
VLP presenting target epitope
Modularize into VLP format
x5
x72
Capsomere presenting target epitope
![Page 22: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/22.jpg)
22
Structural analysis of helix 190 peptide
MD simulationGromacsIn PBS solution
Peptide B1 Peptide B2
Helix 190in native HA
20 ns
![Page 23: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/23.jpg)
23
Module Structure MattersPeptide Recombinant HA
***
***
ns = not significant
***ns
![Page 24: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/24.jpg)
24
Initial Target Epitopes
Strain-specificHA1 – receptor binding regionsOther HA1 epitopesBiology 101
Broadly cross-protectingM2e of matrix protein 2HA stalk regions
AssumeViruses
are Static
![Page 25: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/25.jpg)
25
ImmunogenicBroad cross protectionComplementary mechanism
Matrix Protein M2eInfluenza A virus
http://viromag.files.wordpress.com/2009/02/influenza-virus-diagram.jpg
VP1
x5
Modularize into capsomere format
![Page 26: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/26.jpg)
26
Screening of modularized capsomere
Expression levelSolubility levelDownstream bioprocessing yield
1011 and 2022
![Page 27: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/27.jpg)
27
Modular capsomere
![Page 28: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/28.jpg)
28
Capsomere format improves immunogenicity
Alhydrogel
PBS
p = 0.0005
Endp
oint
titr
e(A
nti-M
2e s
peci
fic Ig
G)
Alhydrogel
1011
![Page 29: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/29.jpg)
29
AlhydrogelAlhydrogel
Modular capsomere 1011 vs 2022
Adjuvant necessary for capsomere format
Excellent epitopetolerance
1011 2022 2022Wild-type capsomere
Little sensitivity to more modules
Excellent IgG titres
Endp
oint
titr
e (A
nti-M
2e s
peci
fic Ig
G)
![Page 30: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/30.jpg)
ConclusionsVLP and capsomere platform developed
Remarkable productivity, protein not virus basedExcellent developability and manufacturabilityExcellent end point titres
Moving to protection studiesMultitude of insertions successfully handled
Flexibility afforded by VLP and Capsomere formats
30
![Page 31: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/31.jpg)
31
Influenza in a Connected World
Identify
ShareControl
![Page 32: New Technology in Vaccine Engineering - RCPA](https://reader034.fdocuments.in/reader034/viewer/2022050520/627298413283011bf854fc3f/html5/thumbnails/32.jpg)
32
Acknowledgements
Dr Linda Lua & UQ Protein Expression Facility